ArticleBMC pharmacology & toxicology2026
Clinical efficacy analysis of secukinumab combined with calcipotriol cream in the treatment of moderate to severe psoriasis in elderly patients.
Article in BMC pharmacology & toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPsoriasis is a chronic immune-mediated inflammatory skin disorder, with plaque psoriasis being the most common clinical subtype, especially in elderly patients. Conventional therapies often provide suboptimal outcomes, necessitating the exploration of novel treatment approaches. This study evaluates the clinical efficacy of combining Secukinumab with Calcipotriol Cream in elderly patients with moderate to severe psoriasis.
methodsA total of 160 elderly patients (≥ 65 years) with plaque psoriasis were retrospectively analyzed between January 2020 and December 2024. All patients received baseline therapy with oral acitretin and topical clobetasol. The observation group (n = 80) additionally received secukinumab and calcipotriol cream. The control group (n = 80) received baseline therapy only. The primary endpoint was overall clinical efficacy based on Psoriasis Area and Severity Index (PASI) improvement. Secondary endpoints included changes in PASI scores, Dermatology Life Quality Index (DLQI), skin barrier parameters (stratum corneum hydration and sebum content), and incidence of adverse events over 12 weeks.
resultsThe total efficacy rate was significantly higher in the observation group than in the control group (90.0% vs. 72.5%, χ² = 8.306, P = 0.040). PASI scores were significantly reduced in both groups, with a greater reduction observed in the observation group (16.12 ± 3.13 vs. 18.98 ± 3.92; P < 0.001). Improvements in stratum corneum hydration (54.08 ± 6.05 vs. 50.20 ± 5.74; P < 0.001) and sebum content (138.20 ± 12.39 vs. 129.72 ± 10.68; P < 0.001) were also greater in the observation group. DLQI scores improved more significantly in the observation group (7.82 ± 1.05 vs. 9.52 ± 1.38; P < 0.001). Adverse events were infrequent and comparable between groups (P = 0.168). Post hoc power analysis confirmed sufficient statistical power (> 80%) across all primary endpoints.
conclusionsThis retrospective study suggests that secukinumab combined with calcipotriol cream improves clinical outcomes and quality of life with good tolerability in elderly patients with moderate to severe psoriasis, supporting its potential therapeutic utility. CLINICAL TRIAL: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.